NASDAQ:CHEK - Check-Cap Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 385.34 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.52
+0.30 (1.20%)

This chart shows the closing price for CHEK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Check-Cap Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHEK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHEK

Analyst Price Target is $2.50
▲ +385.34% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Check-Cap in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 385.34% upside from the last price of $0.52.

This chart shows the closing price for CHEK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Check-Cap. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2021HC WainwrightReiterated RatingBuy$3.00Low
8/9/2021HC WainwrightLower Price TargetBuy$4.00 ➝ $3.00Low
3/17/2021Dawson JamesReiterated RatingBuy ➝ Neutral$2.00Low
3/16/2021HC WainwrightBoost Price TargetBuy$1.50 ➝ $4.00High
11/19/2020HC WainwrightLower Price TargetBuy$2.00 ➝ $1.50Medium
5/28/2020HC WainwrightReiterated RatingBuy$2.00Medium
4/24/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $2.00Medium
12/31/2019HC WainwrightReiterated RatingBuy$15.00Low
12/5/2019Dawson JamesInitiated CoverageBuy$4.00Low
7/10/2019HC WainwrightReiterated RatingBuy$15.00Low
2/5/2019Dougherty & CoInitiated CoverageBuy$6.00High
12/14/2018HC WainwrightSet Price TargetBuy$14.00High
11/6/2018HC WainwrightSet Price TargetBuy$14.00Low
10/10/2018HC WainwrightSet Price TargetBuy$14.00Low
9/5/2018HC WainwrightReiterated RatingBuy$14.00Low
8/1/2018HC WainwrightSet Price TargetBuy$14.00High
6/6/2018HC WainwrightSet Price TargetBuy$14.00Medium
5/23/2018HC WainwrightReiterated RatingBuy ➝ Buy$14.00Medium
3/13/2018HC WainwrightInitiated CoverageBuy$72.00High
1/11/2018HC WainwrightBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.00High
11/28/2017HC WainwrightLower Price TargetBuy ➝ Buy$84.00 ➝ $66.00High
9/28/2017HC WainwrightReiterated RatingBuy ➝ Buy$72.00 ➝ $84.00High
9/27/2017Maxim GroupReiterated RatingBuy$60.00High
8/11/2017HC WainwrightSet Price TargetBuy$72.00High
5/30/2017Maxim GroupReiterated RatingBuyLow
3/12/2017HC WainwrightSet Price TargetBuy$72.00Low
3/11/2017Maxim GroupSet Price TargetBuy$72.00High
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 7 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
7/30/2021
  • 17 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/29/2021
  • 16 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/28/2021
  • 10 very positive mentions
  • 24 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
10/28/2021
  • 5 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
11/27/2021
  • 2 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/27/2021
  • 7 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
1/26/2022

Current Sentiment

  • 7 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Check-Cap logo
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Read More

Today's Range

Now: $0.52
Low: $0.50
High: $0.54

50 Day Range

MA: $0.71
Low: $0.52
High: $0.88

52 Week Range

Now: $0.52
Low: $0.48
High: $4.49

Volume

818,921 shs

Average Volume

1,051,039 shs

Market Capitalization

$49.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Check-Cap?

The following Wall Street analysts have issued reports on Check-Cap in the last year: Dawson James, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CHEK.

What is the current price target for Check-Cap?

2 Wall Street analysts have set twelve-month price targets for Check-Cap in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 385.3%. HC Wainwright has the highest price target set, predicting CHEK will reach $3.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $2.00 for Check-Cap in the next year.
View the latest price targets for CHEK.

What is the current consensus analyst rating for Check-Cap?

Check-Cap currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHEK will outperform the market and that investors should add to their positions of Check-Cap.
View the latest ratings for CHEK.

What other companies compete with Check-Cap?

Other companies that are similar to Check-Cap include Koninklijke Philips, Hologic, Butterfly Network, Nano-X Imaging and Hyperfine.

How do I contact Check-Cap's investor relations team?

Check-Cap's physical mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company's listed phone number is 972546706451 and its investor relations email address is [email protected] The official website for Check-Cap is www.check-cap.com.